Kim J, Gosnell JE, Roman SA (2020) Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol 16(1):17–29
French JD (2020) Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies. Nat Rev Endocrinol 16(11):629–641
Viola D et al (2016) Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer 23(4):R185-205
Article CAS PubMed Google Scholar
Kogai T, Brent GA (2012) The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther 135(3):355–370
Article CAS PubMed PubMed Central Google Scholar
Suzuki K et al (1999) Thyroglobulin regulates follicular function and heterogeneity by suppressing thyroid-specific gene expression. Biochimie 81(4):329–340
Article CAS PubMed Google Scholar
Rowe CW et al (2017) Targeting the TSH receptor in thyroid cancer. Endocr Relat Cancer 24(6):R191–R202
Article CAS PubMed Google Scholar
Carayon P et al (1980) Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab 51(4):915–920
Article CAS PubMed Google Scholar
Singh SP et al (2004) Upon thyrotropin binding the thyrotropin receptor is internalized and localized to endosome. Endocrinology 145(2):1003–1010
Article CAS PubMed Google Scholar
Marcus C et al (2014) PET/CT in the management of thyroid cancers. AJR Am J Roentgenol 202(6):1316–1329
Kist JW et al (2016) 124I PET/CT to predict the outcome of blind 131I treatment in patients with biochemical recurrence of differentiated thyroid cancer: results of a multicenter diagnostic cohort study (THYROPET). J Nucl Med 57(5):701–707
Article CAS PubMed Google Scholar
Samnick S et al (2018) Initial clinical investigation of [18F]Tetrafluoroborate PET/CT in comparison to [124I]Iodine PET/CT for imaging thyroid cancer. Clin Nucl Med 43(3):162–167
Corsetti F et al (2004) Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection. Cancer Biother Radiopharm 19(1):57–63
Gershengorn MC, Neumann S (2012) Update in TSH receptor agonists and antagonists. J Clin Endocrinol Metab 97(12):4287–4292
Article CAS PubMed PubMed Central Google Scholar
Sanders J et al (2010) TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities. Methods Enzymol 485:393–420
Article CAS PubMed Google Scholar
Galli F et al (2014) Tc-99m-Labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer. Thyroid 24(8):1297–1308
Article CAS PubMed PubMed Central Google Scholar
Galli F et al (2021) In vivo imaging of thyroid cancer with Tc-99m-TR1401 and Tc-99m-TR1402: a comparison study in dogs. J Clin Med 10(9):1878
Article CAS PubMed PubMed Central Google Scholar
Gimblet GR et al (2023) Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer. Surgery 175(1):199–206. https://doi.org/10.1016/j.surg.2023.05.045
Furmaniak J et al (2022) TSH receptor specific monoclonal autoantibody K1–70(TM) targeting of the TSH receptor in subjects with Graves’ disease and Graves’ orbitopathy-Results from a phase I clinical trial. Clin Endocrinol (Oxf) 96(6):878–887
Article CAS PubMed Google Scholar
Furmaniak J et al (2019) Preclinical studies on the toxicology, pharmacokinetics and safety of K1–70(TM) a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity. Auto Immun Highlights 10(1):11
Article PubMed PubMed Central Google Scholar
Knowles SM, Wu AM (2012) Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 30(31):3884–3892
Article PubMed PubMed Central Google Scholar
Evans M et al (2010) Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin Endocrinol 73(3):404–412
Núñez Miguel R et al (2022) Structure of full-length TSH receptor in complex with antibody K1–70. J Mol Endocrinol 70(1). https://doi.org/10.1530/JME-22-0120
Sharma SK et al (2021) A systematic evaluation of antibody modification and (89)Zr-radiolabeling for optimized immuno-PET. Bioconjug Chem 32(7):1177–1191
Article CAS PubMed Google Scholar
Vosjan MJ et al (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 5(4):739–743
Article CAS PubMed Google Scholar
Marlow LA et al (2018) Methodology, criteria, and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts. J Clin Endocrinol Metab 103(9):3169–3182
Article PubMed PubMed Central Google Scholar
Demeure MJ et al (1992) Invasion by cultured human follicular thyroid cancer correlates with increased beta 1 integrins and production of proteases. World J Surg 16(4):770–776
Article CAS PubMed Google Scholar
Meares CF et al (1984) Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 142(1):68–78
Article CAS PubMed Google Scholar
Szkudlinski MW et al (2002) Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 82(2):473–502
Article CAS PubMed Google Scholar
Ryder M et al (2021) Blocking the thyrotropin receptor with K1–70 in a patient with follicular thyroid cancer, Graves’ disease, and Graves’ ophthalmopathy. Thyroid 31(10):1597–1602
Moroz A et al (2018) A preclinical assessment of (89)Zr-atezolizumab identifies a requirement for carrier added formulations not observed with (89)Zr-C4. Bioconjug Chem 29(10):3476–3482
Article CAS PubMed PubMed Central Google Scholar
Kist de Ruijter L et al (2021) First-in-human study of the biodistribution and pharmacokinetics of 89Zr-CX-072, a novel immunopet tracer based on an anti-PD-L1 probody. Clin Cancer Res 27(19):5325–5333
Bagriacik EU, Klein JR (2000) The thyrotropin (thyroid-stimulating hormone) receptor is expressed on murine dendritic cells and on a subset of CD45RBhigh lymph node T cells: functional role for thyroid-stimulating hormone during immune activation. J Immunol 164(12):6158–6165
Article CAS PubMed Google Scholar
Abe E et al (2003) TSH is a negative regulator of skeletal remodeling. Cell 115(2):151–162
留言 (0)